Citations (103)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Marzena Staniszewska, Kajetan Kiełbowski, Klaudia Rusińska, Estera Bakinowska, Ewa Gromowska & Andrzej Pawlik. (2023) Targeting cyclin-dependent kinases in rheumatoid arthritis and psoriasis – a review of current evidence. Expert Opinion on Therapeutic Targets 27:11, pages 1097-1113.
Read now
Read now
Marco Galluzzo, Andrea Chiricozzi, Elisa Cinotti, Giovanna Brunasso, Maurizio Congedo, Maria Esposito, Chiara Franchi, Giovanna Malara, Alessandra Narcisi, Stefano Piaserico, Rossana Tiberio, Giuseppe Argenziano, Gabriella Fabbrocini & Aurora Parodi. (2022) Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opinion on Biological Therapy 22:3, pages 367-376.
Read now
Read now
Nikolai Dyrberg Loft, Sofie Vaengebjerg & Lone Skov. (2020) Cancer risk in patients with psoriasis: should we be paying more attention?. Expert Review of Clinical Immunology 16:5, pages 479-492.
Read now
Read now
Szandra Dalmády, Lajos Kemény, Márk Antal & Rolland Gyulai. (2020) Periodontitis: a newly identified comorbidity in psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology 16:1, pages 101-108.
Read now
Read now
Chuanlan Gu & Junyi Yang. (2019) Risankizumab for the treatment of psoriasis. Expert Review of Clinical Pharmacology 12:9, pages 851-857.
Read now
Read now
Lluís Puig. (2019) Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Review of Clinical Immunology 15:6, pages 589-597.
Read now
Read now
Álvaro Machado & Tiago Torres. (2018) Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis: Targets and Therapy 8, pages 83-92.
Read now
Read now
Kristen M Beck, Isabelle M Sanchez, Eric J Yang & Wilson Liao. (2018) Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. Psoriasis: Targets and Therapy 8, pages 49-58.
Read now
Read now
Giuseppe Pistone, Rosario Gurreri, Giovanna Tilotta, Elena Castelli & Maria Rita Bongiorno. (2018) Secukinumab efficacy in the treatment of nail psoriasis: a case series. Journal of Dermatological Treatment 29:sup1, pages 21-24.
Read now
Read now
M. Galluzzo, S. D’Adamio, E. Campione, L. Bianchi & M. Talamonti. (2018) A safety evaluation of guselkumab for the treatment of psoriasis. Expert Opinion on Drug Safety 17:7, pages 741-751.
Read now
Read now
Matteo Megna, Anna Balato, Annunziata Raimondo & Nicola Balato. (2018) Guselkumab for the treatment of psoriasis. Expert Opinion on Biological Therapy 18:4, pages 459-468.
Read now
Read now
Annalisa Tonini, Bruno Gualtieri, Salvatore Panduri, Marco Romanelli & Andrea Chiricozzi. (2018) A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.. Expert Opinion on Biological Therapy 18:2, pages 135-148.
Read now
Read now
Eckart Haneke. (2017) Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. Psoriasis: Targets and Therapy 7, pages 51-63.
Read now
Read now
Caleb Jeon, Sahil Sekhon, Di Yan, Ladan Afifi, Mio Nakamura & Tina Bhutani. (2017) Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Human Vaccines & Immunotherapeutics 13:10, pages 2247-2259.
Read now
Read now
Articles from other publishers (89)
Elena CARMONA-ROCHA & Lluís PUIG. (2023) The biological basis of disease recurrence in psoriasis. Italian Journal of Dermatology and Venereology 158:4.
Crossref
Crossref
Andrew Blauvelt, Andrea Chiricozzi, Benjamin D. Ehst & Mark G. Lebwohl. (2023) Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review. Advances in Therapy 40:8, pages 3410-3433.
Crossref
Crossref
Yeonbin Jeong, Jaeseung Song, Yubin Lee, Eunyoung Choi, Youngtae Won, Byunghyuk Kim & Wonhee Jang. (2023) A Transcriptome-Wide Analysis of Psoriasis: Identifying the Potential Causal Genes and Drug Candidates. International Journal of Molecular Sciences 24:14, pages 11717.
Crossref
Crossref
Husna Kadagothy, Shweta Nene, Etikala Amulya, Ganesh Vambhurkar, A.N. Rajalakshmi, Dharmendra Kumar Khatri, Shashi Bala Singh & Saurabh Srivastava. (2023) Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways. European Journal of Pharmacology 947, pages 175668.
Crossref
Crossref
Matteo Megna, Angelo Ruggiero, Teresa Battista, Laura Marano, Sara Cacciapuoti & Luca Potestio. (2023) Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. Journal of Clinical Medicine 12:9, pages 3233.
Crossref
Crossref
Jing Wang, Yufang Liu, Yuxin Zhang, Shiyan Wang, Shaomei Kang, Ningyu Mi, Ruxin Li & Yulin Zou. (2023) Identification immune response genes in psoriasis after treatment with secukinumab. BMC Medical Genomics 16:1.
Crossref
Crossref
Kim Campbell, Katherine Li, Feifei Yang, Patrick Branigan, M. Merle Elloso, Jacqueline Benson, Yevgeniya Orlovsky, Yanqing Chen, Sandra Garcet & James G. Krueger. (2023) Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab. ImmunoHorizons 7:4, pages 273-285.
Crossref
Crossref
Angela Cappello, Mara Mancini, Stefania Madonna, Serena Rinaldo, Alessio Paone, Claudia ScarponiAntonio Belardo, Lello ZollaAlessandro Zuccotti, Emanuele Panatta, Sabatino PallottaMargherita Annicchiarico-Petruzzelli, Cristina Albanesi, Francesca Cutruzzolà, Lu Wang, Wei Jia, Gerry MelinoEleonora Candi. (2022) Extracellular serine empowers epidermal proliferation and psoriasis-like symptoms. Science Advances 8:50.
Crossref
Crossref
Giampaolo Trevisan, Lerica Germi & Luigi Naldi. (2022) Erythrodermic psoriasis improved by tildrakizumab. Dermatology Reports 14:4.
Crossref
Crossref
Antonella Di Cesare, Federica Ricceri, Elia Rosi, Maria Thais Fastame & Francesca Prignano. (2022) Therapy of PsO in Special Subsets of Patients. Biomedicines 10:11, pages 2879.
Crossref
Crossref
Mariolina Bruno, Linda Davidson, Hans J.P.M. Koenen, Juul M.P.A. van den Reek, Bram van Cranenbroek, Elke M.G.J. de Jong, Frank L. van de Veerdonk, Bart-Jan Kullberg & Mihai G. Netea. (2022) Immunological Effects of Anti‒IL-17/12/23 Therapy in Patients with Psoriasis Complicated by Candida Infections. Journal of Investigative Dermatology 142:11, pages 2929-2939.e8.
Crossref
Crossref
P. Gisondi, M. Maurelli, F. Bellinato & G. Girolomoni. (2022) Is risankizumab as needed administration a good option for patients with plaque psoriasis?. Journal of the European Academy of Dermatology and Venereology 36:9.
Crossref
Crossref
Alessio GAMBARDELLA, Gaetano LICATA, Vittorio TANCREDI, Giulia CALABRESE, Alina DE ROSA, Roberto ALFANO & Giuseppe ARGENZIANO. (2022) A case of refractory palmoplantar psoriasis treated with tildrakizumab. Italian Journal of Dermatology and Venereology 157:4.
Crossref
Crossref
Hai-Feng Zhou, Fa-Xi Wang, Fei Sun, Xin Liu, Shan-Jie Rong, Jia-Hui Luo, Tian-Tian Yue, Jun Xiao, Chun-Liang Yang, Wan-Ying Lu, Xi Luo, Qing Zhou, He Zhu, Ping Yang, Fei Xiong, Qi-Lin Yu, Shu Zhang & Cong-Yi Wang. (2022) Aloperine Ameliorates IMQ-Induced Psoriasis by Attenuating Th17 Differentiation and Facilitating Their Conversion to Treg. Frontiers in Pharmacology 13.
Crossref
Crossref
Lluís Puig, Antonio Costanzo, Ernesto J. Muñoz‐Elías, Maria Jazra, Sven Wegner, Carle F. Paul & Curdin Conrad. (2022) The biological basis of disease recurrence in psoriasis: a historical perspective and current models. British Journal of Dermatology 186:5, pages 773-781.
Crossref
Crossref
Marija V. Medovic, Vladimir Lj. Jakovljevic, Vladimir I. Zivkovic, Nevena S. Jeremic, Jovana N. Jeremic, Sergey B. Bolevich, Ana B. Ravic Nikolic, Vesna M. Milicic & Ivan M. Srejovic. (2022) Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches. Oxidative Medicine and Cellular Longevity 2022, pages 1-17.
Crossref
Crossref
Xiaomin Yao, Zhen Zhu, Upasana Manandhar, Han Liao, Tiexi Yu, Yueying Wang, Yawen Bian, Bo Zhang, Xuanhong Zhang, Jun Xie & Jiquan Song. (2022) RNA-seq reveal RNA binding protein GNL3 as a key mediator in the development of psoriasis vulgaris by regulating the IL23/IL17 axis. Life Sciences 293, pages 119902.
Crossref
Crossref
Elena del Alcázar, Anna López‐Ferrer, Álvaro Martínez‐Doménech, Ricardo Ruiz‐Villaverde, Mª. del Mar Llamas‐Velasco, Vicenç Rocamora, Marc Julià, Jaime Notario, Lourdes Rodríguez Fernández‐Freire, Antonio Sahuquillo‐Torralba, David Vidal, Raquel Rivera, Gregorio Carretero, Almudena Mateu, Pablo Cueva & José Manuel Carrascosa. (2022) Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy 35:2.
Crossref
Crossref
Jeffrey J. Crowley, Richard G. Langley, Kenneth B. Gordon, Andreas Pinter, Laura K. Ferris, Simone Rubant, Huzefa Photowala, Zhenyi Xue, Tianshuang Wu, Tianyu Zhan, Stefan Beeck, Megha Shah & Richard B. Warren. (2022) Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatology and Therapy 12:2, pages 561-575.
Crossref
Crossref
Magdalena Kutwin, Monika Migdalska-Sęk, Ewa Brzeziańska-Lasota, Piotr Zelga & Anna Woźniacka. (2021) An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis. Journal of Clinical Medicine 10:24, pages 5834.
Crossref
Crossref
K.A. Papp, M.G. Lebwohl, L. Puig, M. Ohtsuki, S. Beissert, J. Zeng, S. Rubant, R. Sinvhal, Y. Zhao, A.M. Soliman, G. Alperovich & C. Leonardi. (2021) Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up. British Journal of Dermatology 185:6, pages 1135-1145.
Crossref
Crossref
Vanessa Rocha Ribeiro, Mariana Romao-Veiga, Priscila Rezeck Nunes, Mariana Leticia Matias, Jose Carlos Peracoli & Maria Terezinha Serrao Peracoli. (2021) Vitamin D modulates the transcription factors of T cell subsets to anti-inflammatory and regulatory profiles in preeclampsia. International Immunopharmacology 101, pages 108366.
Crossref
Crossref
Riccardo G. Borroni, Piergiorgio Malagoli, Luigi Gargiulo, Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero Di Corteranzo, Alessandra Narcisi, Michela Ortoncelli, Paolo Dapavo & Antonio Costanzo. (2021) Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study. Acta Dermato-Venereologica 101:11, pages adv00605.
Crossref
Crossref
Esther Lutgens, Jeremie Joffre, Bram van Os & Hafid Ait-Oufella. (2021) Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies. Atherosclerosis 335, pages 98-109.
Crossref
Crossref
Egídio Freitas, Andrew Blauvelt & Tiago Torres. (2021) Bimekizumab for the Treatment of Psoriasis. Drugs 81:15, pages 1751-1762.
Crossref
Crossref
Kilian Eyerich, Peter Weisenseel, Andreas Pinter, Knut Schäkel, Khusru Asadullah, Sven Wegner, Ernesto J Muñoz-Elias, Holger Bartz, Friedmann J H Taut & Kristian Reich. (2021) IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open 11:9, pages e049822.
Crossref
Crossref
Abdulmajeed M Alajlan & Tala A Qadoumi. (2021) Palmoplantar Psoriasis Successfully Treated With Risankizumab. Cureus.
Crossref
Crossref
Jiang-Min Liu, Quan-Xin Jin, Manabu Fujimoto, Fang-Fang Li, Lin-Bo Jin, Ran Yu, Guang-Hai Yan, Lian-Hua Zhu, Fan-Ping Meng, Qing-Gao Zhang & Gui-Hua Jin. (2021) Dihydroartemisinin Alleviates Imiquimod-Induced Psoriasis-like Skin Lesion in Mice Involving Modulation of IL-23/Th17 Axis. Frontiers in Pharmacology 12.
Crossref
Crossref
Feras M. Ghazawi, Farhan Mahmood, Leon Kircik, Yves Poulin, Marc Bourcier, Ronald Vender, Marni C. Wiseman, Charles Lynde & Ivan V. Litvinov. (2021) A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Frontiers in Medicine 8.
Crossref
Crossref
Yaohan Xu, Jiang Zhu, Jingyi Hu, Ziqi Zou, Yueling Zhao, Lihua Lai, Ping Xu, Yinjing Song & Hao Cheng. (2021) L-Theanine Alleviates IMQ-Induced Psoriasis Like Skin Inflammation by Downregulating the Production of IL-23 and Chemokines. Frontiers in Pharmacology 12.
Crossref
Crossref
I-Hsin Huang, Po-Chien Wu, Ting-Hua Yang, Hua Li, Yu-Ting Huang, Ying-Chih Cheng, Po-Hsiu Kuo, Ya-Han Lee, Yu-Chen Huang & Yu-Kang Tu. (2021) Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis. Journal of the American Academy of Dermatology 85:1, pages 135-143.
Crossref
Crossref
O. V. Zhukova, E. I. Kasikhina, M. N. Ostretsova & N. N. Potekaev. (2021) New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab. Meditsinskiy sovet = Medical Council:8, pages 40-50.
Crossref
Crossref
Roberto Russo, Giulia Gasparini, Emanuele Cozzani, Martina Burlando & Aurora Parodi. (2021)
Considerations on inhibition of
IL
‐23 in psoriatic women of childbearing potential
. Dermatologic Therapy 34:3.
Crossref
Crossref
Kim A. Papp, Saskia de Vente, Jiewei Zeng, Mary Flack, Byron Padilla & Stephen K. Tyring. (2021) Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial. Dermatology and Therapy 11:2, pages 487-497.
Crossref
Crossref
Alan Menter, Gerald G. Krueger, So Yeon Paek, Dario Kivelevitch, Iannis E. Adamopoulos & Richard G. Langley. (2021) Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatology and Therapy 11:2, pages 385-400.
Crossref
Crossref
David E. Ochayon & Stephen N. Waggoner. (2021) The Effect of Unconventional Cytokine Combinations on NK-Cell Responses to Viral Infection. Frontiers in Immunology 12.
Crossref
Crossref
Hanae Miyagawa, Hiromichi Hara, Jun Araya, Shunsuke Minagawa, Takanori Numata, Yoshinori Umezawa, Akihiko Asahina, Hidemi Nakagawa & Kazuyoshi Kuwano. (2021) Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis. PLOS ONE 16:1, pages e0245284.
Crossref
Crossref
Dong-Kyun Hong, Mi-Ra Choi, Yul-Lye Hwang, Jae Kyung Lee, Young Lee, Young-Joon Seo, Sooil Kim, Young-Ho Lee, Chang-Deok Kim & Jeung-Hoon Lee. (2021)
Potential Role of Cytosolic RNA Sensor
MDA5
as an Inhibitor for Keratinocyte Differentiation in the Pathogenesis of Psoriasis
. Annals of Dermatology 33:4, pages 339.
Crossref
Crossref
Teng‐Li Lin & Yi‐Ju Chen. (2020) Successful treatment with ixekizumab in a guselkumab‐resistant psoriasis patient. Dermatologic Therapy 34:1.
Crossref
Crossref
Shanshan Xu, Xing Gao, Jixiang Deng, Jiajia Yang & Faming Pan. (2021) Vergleich der Wirksamkeit und Sicherheit von Biologika bei mittelstark bis stark ausgeprägter Plaque‐Psoriasis: Metaanalyse multipler Therapien. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 19:1, pages 47-57.
Crossref
Crossref
Shanshan Xu, Xing Gao, Jixiang Deng, Jiajia Yang & Faming Pan. (2020) Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple‐treatments meta‐analysis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 19:1, pages 47-56.
Crossref
Crossref
R.B. Warren, A. Blauvelt, Y. Poulin, S. Beeck, M. Kelly, T. Wu, Z. Geng & C. Paul. (2020) Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*. British Journal of Dermatology 184:1, pages 50-59.
Crossref
Crossref
Camila Cataldi de Alcantara, Edna Maria Vissoci Reiche & Andréa Name Colado Simão. 2021.
171
204
.
Hee J. Kim & Mark G. Lebwohl. 2021. Comprehensive Dermatologic Drug Therapy. Comprehensive Dermatologic Drug Therapy
302
311.e2
.
Deep Joshipura, Brooke Rothstein & David Rosmarin. 2021. Advances in Psoriasis. Advances in Psoriasis
213
224
.
Zaruhi Hovhannisyan, Nengyin Liu, Sara Khalil-AgueroCasandra PaneaJeffrey VanValkenburghRuoyu ZhangWei Keat Lim, Yu BaiWen Fury, Tammy HuangElena Garnova, Jeanette Fairhurst, Jee KimSmita AryalDharani Ajithdoss, Adelekan Oyejide, Maria del Pilar Molina-Portela, Hock E, William Poueymirou, Nicole Stokes Oristian, Susannah Brydges, Xia Liu, William Olson, George YancopoulosAndrew J. Murphy, Matthew A. Sleeman & Sokol Haxhinasto. (2020) Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine. Science Immunology 5:54.
Crossref
Crossref
Vasann Saranya, Saranya Kuppusamy, Pravati Pal, Munisamy Malathi, Medha Rajappa & Jean Fredrick. (2020) Pulmonary function severity in relation to interleukin-23 levels in patients with psoriasis vulgaris. Journal of Basic and Clinical Physiology and Pharmacology 31:6.
Crossref
Crossref
Atrin Toussi, Natalia Maverakis, Stephanie T. Le, Soumajyoti Sarkar, Smriti K. Raychaudhuri & Siba P. Raychaudhuri. (2020) Updated therapies for the management of Psoriatic Arthritis. Clinical Immunology 220, pages 108536.
Crossref
Crossref
Thomas Kerbusch, Hanbin Li, Russell Wada, Petra M. Jauslin & Larissa Wenning. (2020) Exposure–response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials. British Journal of Clinical Pharmacology 86:9, pages 1795-1806.
Crossref
Crossref
Mohamed A. Alfaleh, Hashem O. Alsaab, Ahmad Bakur Mahmoud, Almohanad A. Alkayyal, Martina L. Jones, Stephen M. Mahler & Anwar M. Hashem. (2020) Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Frontiers in Immunology 11.
Crossref
Crossref
A. Egeberg, P. Gisondi, J.M. Carrascosa, R.B. Warren & U. Mrowietz. (2020) The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. Journal of the European Academy of Dermatology and Venereology 34:8, pages 1695-1706.
Crossref
Crossref
J. Diels, P. Thilakarathne, C. Cameron, S. McElligott, A. Schubert & L. Puig. (2020) Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis. British Journal of Dermatology 183:2, pages 276-284.
Crossref
Crossref
Shoban Babu Varthya, Pugazhenthan Thangaraju, Sajitha Venkatesan, A. R. Vijayakumar & Eswaran Thangaraju. (2020) A Nonsystematic Review on Risankizumab: a Novel Drug Recently Approved for Moderate to Severe Psoriasis. SN Comprehensive Clinical Medicine 2:8, pages 1174-1180.
Crossref
Crossref
Chun-Ming Shih, Chi-Kun Hsieh, Chien-Yu Huang, Chun-Yao Huang, Kuo-Hsien Wang, Tsorng-Harn Fong, Nguyen Thi Thu Trang, Kuan-Ting Liu & Ai-Wei Lee. (2020) Lycopene Inhibit IMQ-Induced Psoriasis-Like Inflammation by Inhibiting ICAM-1 Production in Mice. Polymers 12:7, pages 1521.
Crossref
Crossref
Chunlei Sun & Jianxin Xia. (2020) Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. Minerva Medica 111:3.
Crossref
Crossref
Lili Chen, Madhura Deshpande, Marcos Grisotto, Paola Smaldini, Roberto Garcia, Zhengxiang He, Percio S. Gulko, Sergio A. Lira & Glaucia C. Furtado. (2020) Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Scientific Reports 10:1.
Crossref
Crossref
Cristina López-Sánchez & Lluís Puig. (2020) Guselkumab in the treatment of moderate-to-severe plaque psoriasis. Immunotherapy 12:6, pages 355-371.
Crossref
Crossref
Perla Lansang, James N. Bergman, Loretta Fiorillo, Marissa Joseph, Irene Lara-Corrales, Danielle Marcoux, Catherine McCuaig, Elena Pope, Vimal H. Prajapati, Sue Z.J. Li & Ian Landells. (2020) Management of pediatric plaque psoriasis using biologics. Journal of the American Academy of Dermatology 82:1, pages 213-221.
Crossref
Crossref
Lorena Tonarelli. (2019) Translating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment. European Medical Journal, pages 16-22.
Crossref
Crossref
Linda Serrano, Victoria Maloney & Kenneth B Gordon. (2019) Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy 11:16, pages 1357-1370.
Crossref
Crossref
Aviad Keren, Amos Gilhar, Yehuda Ullmann, Marina Zlotkin‐Frušić, Yoram Soroka, Abraham J. Domb & Mia Levite. (2019) Instantaneous depolarization of T cells via dopamine receptors, and inhibition of activated T cells of Psoriasis patients and inflamed human skin, by D1‐like receptor agonist: Fenoldopam. Immunology 158:3, pages 171-193.
Crossref
Crossref
Helen Saul. (2019) Is Complete Skin Clearance in Psoriasis the Answer?. EMJ Dermatology, pages 53-61.
Crossref
Crossref
Shanshan Xu, Xiaoyi Zhang, Meijuan Pan, Zongwen Shuai, Shengqian Xu & Faming Pan. (2019) Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis. International Immunopharmacology 75, pages 105841.
Crossref
Crossref
Katarzyna Banaszczyk. (2019) Tildrakizumab in the treatment of psoriasis – literature review. Rheumatology 57:4, pages 234-238.
Crossref
Crossref
Guoliang Deng, Wenjun Chen, Peng Wang, Tianying Zhan, Wei Zheng, Zhengbing Gu, Xiaomei Wang, Xiaoyun Ji & Yang Sun. (2019) Inhibition of NLRP3 inflammasome-mediated pyroptosis in macrophage by cycloastragenol contributes to amelioration of imiquimod-induced psoriasis-like skin inflammation in mice. International Immunopharmacology 74, pages 105682.
Crossref
Crossref
Joel Reis, Ron Vender & Tiago Torres. (2019) Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. BioDrugs 33:4, pages 391-399.
Crossref
Crossref
Megan Breuer. (2019) Fine-Tuning the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway. EMJ Rheumatology, pages 61-70.
Crossref
Crossref
Rachel G. Casseres & David Rosmarin. (2019) Two Cases of Worsening Psoriasis After Switching From Ustekinumab to Guselkumab. Journal of Psoriasis and Psoriatic Arthritis 4:3, pages 153-154.
Crossref
Crossref
Tomaz Lunder, Mateja S. Zorko, Natasa K. Kolar, Aleksandra B. Suhodolcan, Maruska Marovt, Nada K. Leskovec & Pij B. Marko. (2019) Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. International Journal of Dermatology 58:6, pages 631-641.
Crossref
Crossref
Laura Leys, Yibing Wang, Stephanie Paulsboe, Rebecca Edelmayer, Katie Salte, Joseph Wetter, Marian Namovic, Lucy Phillips, Robert Dunstan, Donna Gauvin, Diana Donnelly‐Roberts, Zhi Su, Prisca Honore & Steve McGaraughty. (2019) Characterization of psoriasiform dermatitis induced by systemic injection of interleukin‐23 minicircles in mice. The Journal of Dermatology 46:6, pages 482-497.
Crossref
Crossref
Yibing Wang, Rebecca Edelmayer, Joe Wetter, Katherine Salte, Donna Gauvin, Laura Leys, Stephanie Paulsboe, Zhi Su, Isaac Weinberg, Marian Namovic, Stephen B. Gauld, Prisca Honore, Victoria E. Scott & Steve McGaraughty. (2019) Monocytes/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation. Scientific Reports 9:1.
Crossref
Crossref
Kory P. Schrom, Avi Bitterman & Neil J. Korman. (2019) Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature. Current Dermatology Reports 8:1, pages 6-13.
Crossref
Crossref
Jennifer C. Bares & Mark G. Lebwohl. (2019) Update on Risankizumab for Psoriasis. Current Dermatology Reports 8:1, pages 1-5.
Crossref
Crossref
B. Strober, J. Crowley, R.G. Langley, K. Gordon, A. Menter, C. Leonardi, D. Arikan & W.C. Valdecantos. (2018) Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. Journal of the European Academy of Dermatology and Venereology 32:12, pages 2126-2133.
Crossref
Crossref
Andrew Blauvelt & Andrea Chiricozzi. (2018) The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clinical Reviews in Allergy & Immunology 55:3, pages 379-390.
Crossref
Crossref
Wolf-Henning Boehncke & Nicolo Costantino Brembilla. (2017) Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment. Clinical Reviews in Allergy & Immunology 55:3, pages 295-311.
Crossref
Crossref
Stephen B. Gauld, Donna Gauvin, Lauren Olson, Laura Leys, Stephanie Paulsboe, Zheng Liu, Rebecca M. Edelmayer, Joseph Wetter, Katherine Salte, Yibing Wang, Susan Huang, Prisca Honore & Steven McGaraughty. (2018) Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery. Journal of Dermatological Science 92:1, pages 45-53.
Crossref
Crossref
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin M Valdes, Elizabeth H Z Thompson & Hervé Bachelez. (2018) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet 392:10148, pages 650-661.
Crossref
Crossref
M.J. Gooderham, K.A. Papp & C.W. Lynde. (2018) Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. Journal of the European Academy of Dermatology and Venereology 32:7, pages 1111-1119.
Crossref
Crossref
Elizabeth N. Ergen & Nabiha Yusuf. (2018) Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?. Experimental Dermatology 27:7, pages 737-747.
Crossref
Crossref
Natalie Garzorz-Stark, Felix Lauffer, Linda Krause, Jenny Thomas, Anne Atenhan, Regina Franz, Sophie Roenneberg, Alexander Boehner, Manja Jargosch, Richa Batra, Nikola S. Mueller, Stefan Haak, Christina Groß, Olaf Groß, Claudia Traidl-Hoffmann, Fabian J. Theis, Carsten B. Schmidt-Weber, Tilo Biedermann, Stefanie Eyerich & Kilian Eyerich. (2018) Toll-like receptor 7/8 agonists stimulate plasmacytoid dendritic cells to initiate TH17-deviated acute contact dermatitis in human subjects. Journal of Allergy and Clinical Immunology 141:4, pages 1320-1333.e11.
Crossref
Crossref
Adriana Bojko, Roksana Ostasz, Monika Białecka, Adam Klimowicz, Damian Malinowski, Robert Budawski, Piotr Bojko, Marek Droździk & Mateusz Kurzawski. (2018) IL12B , IL23A , IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment. Human Immunology 79:4, pages 213-217.
Crossref
Crossref
Vanessa K. Ridaura, Nicolas Bouladoux, Jan Claesen, Y. Erin Chen, Allyson L. Byrd, Michael G. Constantinides, Eric D. Merrill, Samira Tamoutounour, Michael A. Fischbach & Yasmine Belkaid. (2018)
Contextual control of skin immunity and inflammation by
Corynebacterium
. Journal of Experimental Medicine 215:3, pages 785-799.
Crossref
Crossref
Charlie Bridgewood, Gareth W. Fearnley, Anna Berekmeri, Philip Laws, Tom Macleod, Sreenivasan Ponnambalam, Martin Stacey, Anne Graham & Miriam Wittmann. (2018) IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis. Frontiers in Immunology 9.
Crossref
Crossref
Katarzyna Bocheńska, Elwira Smolińska, Marta Moskot, Joanna Jakóbkiewicz-Banecka & Magdalena Gabig-Cimińska. (2017) Models in the Research Process of Psoriasis. International Journal of Molecular Sciences 18:12, pages 2514.
Crossref
Crossref
Mio Nakamura, Katherine Lee, Caleb Jeon, Sahil Sekhon, Ladan Afifi, Di Yan, Kristina Lee & Tina Bhutani. (2017) Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatology and Therapy 7:3, pages 281-292.
Crossref
Crossref
Jose-Manuel Carrascosa. (2017) Nuevos tratamientos en psoriasis. Medicina Clínica 149:4, pages 157-159.
Crossref
Crossref
Jose-Manuel Carrascosa. (2017) New treatments in psoriasis. Medicina Clínica (English Edition) 149:4, pages 157-159.
Crossref
Crossref
Kunal Malik & Emma Guttman-Yassky. (2017) Systemic Therapy of Atopic Dermatitis: When, How, for How Long?. Current Dermatology Reports 6:2, pages 149-160.
Crossref
Crossref